Diagnostics Platform

Improve link to care

The growing challenges of pandemic risk management for infectious diseases drives the need for decentralized diagnostic solutions. More than 120 million high-risk populations need to be screened on an infectious disease panel in western countries alone. That is why European health authorities and WHO are both looking for assays providing full serological status on the 3 mains blood borne diseases: hepatitis B and C and HIV.

To fulfill this need, MagIA diagnostic develops a platform that enables the detection of infection diseases panels. The in vitro diagnostic platform is dedicated to point of care multiplex panel testing using capillary blood. MagIA detects 3 to 6 parameters in only 20 minutes based on a combination of “equipment and consumables”.

MagIA analyzer

Our key for a flexible and simple solution

MagIA diagnostics analyzer presents many benefits: 

    • Portability, with a battery autonomy of up to 8 hours,
    • Analyze of either 1 or 2 cartridges in parallel,
    • Objective and qualitative results of 3 to 6 parameters in 20 minutes.

MagIA analyzer can be upgraded using the following accessories:

    • mini-printer, for patient results printing,
    • barcode scanner, for patient input identification,
    • a spare battery, to double the systems autonomy,
    • a backpack for secure transportation to your point of need.

 

MagIA kit

The simple way of blood sampling

Each MagIA kits is composed of a cartridge, a lancet, a pipette and a pre-filled diluent bottle.

How does it work?

  1. Collect 50 µl capillary blood using lancet and pipette
  2. Dilute blood in the bottle
  3. Fill 1 or 2 cartridge(s) 
  4. Insert cartridges in MagIA analyzer
  5. Get 3 to 6 results in 20 minutes

 

Benefits

Innovative rapid and portable panel testing

MagIA point of care assays are first near patient testing that detect 6 parameters of HBV, HCV and HIV using 50 µl of capillary blood with results in 20 minutes.

MagIA assays are: 

Flexible: Depending on patient profile & risks, possibility of testing 3 or 6 parameters.

Simple: The tests work with capillary blood. The analyzer interface is simple and intuitive.

Safe: Objective results are delivered by analyzer. 2 internal controls ensure the validity of the results.

Generic: Our platform is generic so that any immunological test or panel can be implemented.

Blood borne diseases screening panel

Syndromic screening of HIV, Hepatitis B and Hepatitis C

 

MagIA diagnostics infectious diseases panel detects Hepatitis B, Hepatitis C and HIV all in once. The rapid and accurate knowledge of the presence or absence of the related pathogens help make timely decisions about treatment, vaccination, and infection control. MagIA diagnostics will decline this panel in 3 kits for modular diagnostic approach: from a single capillary blood sample, MagIA infectious diseases panel detects the pathogens that most commonly present a co-infection: Hepatitis B, Hepatitis C and HIV.

MagIA panel properties
Easy preparation Collect 50 µl of sample, dilute in the provided bottle and inject into 1 or 2 cartridges
Time to results 20 minutes after cartridge(s) insertion in MagIA Analyzer
Sample Capillary blood, veinous blood, serum, plasma
Shelf life 12 months
Storage 10 – 37°C

MagIA HBV-HCV-HIV first assay is dedicated to multiparametric rapid testing of hepatitis B, C and HIV all in once. By detecting the Hepatitis B Surface Antigen (HbsAg), along with HCV and HIV-1/2 antibodies, this assay allows for simultaneous detection of 3 main blood borne diseases.

Our MagIA HCV-HIV2 assay is dedicated to multiparametric rapid testing of hepatitis C and HIV. By detecting HIV-1/2 antibodies, p24 antigen and HCV antibodies, this assay allows for rapid early detection of HIV infection and/or present or past HCV infection.

Our MagIA HBV3 assay is dedicated to multiparametric rapid testing of hepatitis B. By identifying the presence of the Hepatitis B Surface Antigen (HbsAg), along with related antibodies anti-HBs and anti-HBc, this kit allows for a rapid decision between Hepatitis B infection and vaccination.

 

 

Syphilis

Syphilis detection will be implemented into blood borne diseases screening panel to integrate the recrudescence of this infectious disease.

Tropical fever cartridge

A tropical fever kit will allow the parallel detection of Dengue fever, Chikungunya and Zika.